Over 118,000 women are newly diagnosed with gynecologic cancer annually in the U.S.¹
NeoGenomics gynecologic cancer solution supports the care continuum with tests that detect genomic alterations relevant to diagnosis, therapy selection, prognosis, and clinical trial options With deep genomic expertise and a commitment to precision, NeoGenomics empowers clinicians to deliver more informed, targeted care for patients facing gynecologic cancers.
NeoTYPE® Ovarian Tumor Profile
14 Days turnaround time
NEO PanTracer Tissue + HRD
NGS comprehensive genomic profile targeting 517 genes in DNA and RNA for SNVs, InDels, CNVs, RNA fusions/splice variants with MSI and TMB for pan-solid tumors, and HRD for ovarian tumors.
8-10 Days turnaround time